Novo Nordisk’s recent surge in market capitalization has highlighted the growing popularity of semaglutides, a new class of weight loss drugs. These drugs are showing promise as a less invasive alternative to injections like Ozempic, and are attracting interest from consumers and manufacturers alike. Social listening tools, powered by artificial intelligence (AI), are proving invaluable in monitoring and understanding the rapidly growing conversation around semaglutides online. By analyzing consumer posts, CPGs can identify emerging need spaces, understand brand perception, and anticipate future consumer demand.